Literature DB >> 21956693

CD22 serves as a receptor for soluble IgM.

Takahiro Adachi1, Satoru Harumiya, Hiromu Takematsu, Yasunori Kozutsumi, Matthias Wabl, Manabu Fujimoto, Thomas F Tedder.   

Abstract

CD22 (Siglec-2) is a B-cell membrane-bound lectin that recognizes glycan ligands containing α2,6-linked sialic acid (α2,6Sia) and negatively regulates signaling through the B-cell Ag receptor (BCR). Although CD22 has been investigated extensively, its precise function remains unclear due to acting multiple phases. Here, we demonstrate that CD22 is efficiently activated in trans by complexes of Ag and soluble IgM (sIgM) due to the presence of glycan ligands on sIgM. This result strongly suggests sIgM as a natural trans ligand for CD22. Also, CD22 appears to serve as a receptor for sIgM, which induces a negative feedback loop for B-cell activation similar to the Fc receptor for IgG (FcγRIIB).
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956693     DOI: 10.1002/eji.201141899

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

2.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

3.  T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies.

Authors:  Constanze Hess; André Winkler; Alexandra K Lorenz; Vivien Holecska; Véronique Blanchard; Susanne Eiglmeier; Anna-Lena Schoen; Josephine Bitterling; Alexander D Stoehr; Dominique Petzold; Tim Schommartz; Maria M M Mertes; Carolin T Schoen; Ben Tiburzy; Anne Herrmann; Jörg Köhl; Rudolf A Manz; Michael P Madaio; Markus Berger; Hedda Wardemann; Marc Ehlers
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

4.  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Authors:  Chih-Hang Tang; Shiun Chang; Ayumi Hashimoto; Yi-Ju Chen; Chang Won Kang; Anthony R Mato; Juan R Del Valle; Dmitry I Gabrilovich; Chih-Chi Hu
Journal:  Cancer Immunol Res       Date:  2018-04-12       Impact factor: 11.151

Review 5.  Selective IgM Deficiency: Clinical and Laboratory Features of 17 Patients and a Review of the Literature.

Authors:  Zita Chovancova; Pavlina Kralickova; Alena Pejchalova; Marketa Bloomfield; Jana Nechvatalova; Marcela Vlkova; Jiri Litzman
Journal:  J Clin Immunol       Date:  2017-07-21       Impact factor: 8.317

Review 6.  The long elusive IgM Fc receptor, FcμR.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; Dewitt Jones; Naonori Nishida; Toshio Miyawaki; Luigi F Bertoli; Sheila K Sanders; Kazuhito Honjo
Journal:  J Clin Immunol       Date:  2014-05-03       Impact factor: 8.317

Review 7.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

8.  CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.

Authors:  Jennifer Müller; Ingrid Obermeier; Miriam Wöhner; Carolin Brandl; Sarah Mrotzek; Sieglinde Angermüller; Palash C Maity; Michael Reth; Lars Nitschke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

Review 9.  Sialic acids and autoimmune disease.

Authors:  Vinay S Mahajan; Shiv Pillai
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

10.  FcγRIIb and BAFF differentially regulate peritoneal B1 cell survival.

Authors:  María C Amezcua Vesely; Marc Schwartz; Daniela A Bermejo; Carolina L Montes; Kelly M Cautivo; Alexis M Kalergis; David J Rawlings; Eva V Acosta-Rodríguez; Adriana Gruppi
Journal:  J Immunol       Date:  2012-04-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.